Evidence map›Paper›PMID 41599670›Full record

ArticlePharmaceuticals (Basel, Switzerland)2025

Pharmacogenomics of Sorafenib in Hepatocellular Carcinoma (HCC): A LncRNA-Expression Guided Approach Using UCA1 and MALAT1 for Personalizing Therapy in a 154-Patient Cohort.

Mahmoud Nazih, Imam Waked, Shimaa Abdelsattar, Hiba S Al-Amodi, Hala F M Kamel, Muhammad Mahmoud Attia, Ahmed I Khoder, Sahar Badr Hassan, Mohamed Mahmoud Abdel-Latif

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mahmoud NazihDepartment of Clinical Pharmacy, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.
Imam WakedHepatology and Gastroenterology Department, National Liver Institute (NLI), Menoufia University, Shebin El-Kom 32511, Egypt.ORCID 0000-0002-9857-8972
Shimaa AbdelsattarClinical Biochemistry and Molecular Diagnostics, National Liver Institute (NLI), Menoufia University, Shebin El-Kom 35211, Egypt.ORCID 0000-0002-3993-5378
Hiba S Al-AmodiBiochemistry Department, Faculty of Medicine, Umm Al-Qura University, Makkah 21955, Saudi Arabia.ORCID 0000-0003-1865-0004
Hala F M KamelBiochemistry Department, Faculty of Medicine, Umm Al-Qura University, Makkah 21955, Saudi Arabia.
Muhammad Mahmoud AttiaSoftware Engineer, Cairo 11837, Egypt.
Ahmed I KhoderScientific Office, Egyptian Society of Pharmacogenomics and Personalized Medicine (ESPM), Cairo 11562, Egypt.ORCID 0009-0006-1802-4504
Sahar Badr HassanDepartment of Clinical Pharmacy, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.ORCID 0000-0002-7438-4823
Mohamed Mahmoud Abdel-LatifDepartment of Clinical Pharmacy, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

drug resistancehepatocellular carcinoma (HCC)lncRNAMALAT1personalized therapypharmacogenomicssorafenibUCA1

Identifiers

PMID41599670
PMCPMC12844796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.